New ADtect blood test show high accuracy rate for AD diagnosis
DiaGenic has claimed a significant improvement in overall accuracy of a new version of its patented and CE-marked product, ADtect. The data, representing the fourth independent patient study to improve ADtect for blood-based diagnosis of Alzheimer's disease (AD), revealed an accuracy of 82 per cent of AD dementia versus matched control patients.
The higher diagnostic accuracy is obtained from a read-out of 20 genes derived from ADtect, which contains a larger (96) set of genes relevant for the diagnosis of AD. The same selected 20 genes were also tested in two cohorts of patients with amnestic mild cognitive impairment (MCI) that within two years developed AD (MCI/AD) and showed a prediction accuracy for MCI/AD of 70 to 74 per cent versus matched stable MCI (MCI that did not convert to AD). An additional separate 25 non-overlapping gene signature with improved overall prediction was identified predicting conversion from MCI to AD (MCI/AD) with accuracy of 81 per cent.